F M Muggia|T Fojo - JoVE Visualize

Showing results (61-70 of 323) with videos related to

Pageof 33

Sort By:

Medical and Pediatric Oncology|January 1, 1976

Overview of early and investigational chemotherapeutic agents in solid tumorsM Rozencweig, M Slavik, F M Muggia, et al.

Biochemical Pharmacology|May 1, 1987

Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitroS Wadler, M D Green, R Basch, et al.

Cancer Investigation|January 1, 1989

Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndromeA Chachoua, M D Green, F Valentine, et al.

Cancer|August 1, 1978

The chemotherapy of Hodgkin's disease: past experiences and future directionsV T DeVita, B J Lewis, M Rozencweig, et al.

Cancer Chemotherapy and Pharmacology|June 10, 1998

Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology GroupF M Muggia, J A Blessing, H D Homesley, et al.

Anticancer Research|January 1, 1981

Cisplatin: impact of a new anticancer agent on current therapeutic strategiesM Rozencweig, R Abele, D D von Hoff, et al.

Cancer Treatment Reports|April 1, 1984

Activity of mitolactol in cancer of the uterine cervixV Lira-Puerto, F Morales-Canfield, J Wernz, et al.

The Journal of Clinical Endocrinology and Metabolism|February 7, 2001

Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cellsM Kitazono, Y Chuman, T Aikou, et al.

Current Drug Targets|May 12, 2004

Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attackW D Stein, S E Bates, T Fojo

Japanese Journal of Cancer Research : Gann|September 27, 2001

Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressureY Matsumoto, H Takano, S Nagao, et al.

Pageof 33

Showing results (61-70 of 323) with videos related to

Sort By:

Pageof 33

Medical and Pediatric Oncology|January 1, 1976

Overview of early and investigational chemotherapeutic agents in solid tumorsM Rozencweig, M Slavik, F M Muggia, et al.

Biochemical Pharmacology|May 1, 1987

Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitroS Wadler, M D Green, R Basch, et al.

Cancer Investigation|January 1, 1989

Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndromeA Chachoua, M D Green, F Valentine, et al.

Cancer|August 1, 1978

The chemotherapy of Hodgkin's disease: past experiences and future directionsV T DeVita, B J Lewis, M Rozencweig, et al.

Cancer Chemotherapy and Pharmacology|June 10, 1998

Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology GroupF M Muggia, J A Blessing, H D Homesley, et al.

Anticancer Research|January 1, 1981

Cisplatin: impact of a new anticancer agent on current therapeutic strategiesM Rozencweig, R Abele, D D von Hoff, et al.

Cancer Treatment Reports|April 1, 1984

Activity of mitolactol in cancer of the uterine cervixV Lira-Puerto, F Morales-Canfield, J Wernz, et al.

The Journal of Clinical Endocrinology and Metabolism|February 7, 2001

Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cellsM Kitazono, Y Chuman, T Aikou, et al.

Current Drug Targets|May 12, 2004

Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attackW D Stein, S E Bates, T Fojo

Japanese Journal of Cancer Research : Gann|September 27, 2001

Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressureY Matsumoto, H Takano, S Nagao, et al.

Pageof 33